{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:23:36Z","timestamp":1782743016712,"version":"3.54.5"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Rhabdomyolysis is a potentially fatal adverse reaction mostly triggered by certain medications. Few real-world studies have shown a clear association between newer-generation anti-seizure medications (ASMs) and rhabdomyolysis. We sought to quantify the risk and evaluate the clinical features and management of rhabdomyolysis associated with newer-generation ASMs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Data were retrieved from the US FDA Adverse Event Reporting System database (FAERS) from 2018 to 2022 on newer-generation ASMs to identify rhabdomyolysis events, and disproportionality analyses were conducted by estimating the reporting odds ratios (RORs) and corresponding 95% confidence intervals (CIs). Furthermore, case reports from 2012 to 31 December 2022 on newer-generation ASMs-induced rhabdomyolysis were retrieved for retrospective analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 1,130 rhabdomyolysis reports from the FAERS database were considered. Levetiracetam had the greatest proportion and the highest positive signal values of rhabdomyolysis. The RORs (95% CIs) for newer-generation ASMs were, in descending order, levetiracetam 8.01 (7.26\u20138.84), lamotrigine 3.78 (3.25\u20134.40), oxcarbazepine 3.47 (2.53\u20134.75), pregabalin 2.75 (2.43\u20133.12), lacosamide 1.85 (1.29\u20132.65), topiramate 1.64 (1.25\u20132.15), and gabapentin 1.32 (1.13\u20131.55). Twenty-six case reports showed evidence of rhabdomyolysis, and levetiracetam (65.4%) was the most frequently reported agent. The median age was 32\u00a0years; typical initial symptoms included muscle weakness (34.8%), myalgia (34.8%), backache (17.4%), fatigue (13.0%) and leg pain (8.7%). The median time to onset of rhabdomyolysis was 2\u00a0days. All cases had elevated creatine phosphokinase (CPK), and some cases were accompanied by elevated creatinine (57.1%) and myoglobinuria (53.8%). Cessation of ASMs could lead to complete clinical remission. The median time for creatine phosphokinase (CPK) normalization was 8\u00a0days.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This study identified 7 newer-generation ASMs with significant rhabdomyolysis reporting associations. Prescribers should be more aware of this risk and teach patients to recognize rhabdomyolysis signs\/symptoms early.<\/jats:p>","DOI":"10.3389\/fphar.2023.1197470","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:15:31Z","timestamp":1696259731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhenzhen","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ebcr.2014.08.001","article-title":"A case of rhabdomyolysis in which levetiracetam was suspected as the cause","volume":"2","author":"Akiyama","year":"2014","journal-title":"Epilepsy Behav. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e25183","DOI":"10.7759\/cureus.25183","article-title":"Suspected levetiracetam-induced acute rhabdomyolysis in a patient with retinoblastoma: A case report and literature review","volume":"14","author":"Alshehabi","year":"2022","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-0039-1700951","article-title":"Levetiracetam treatment-associated acute rhabdomyolysis in an adolescent","volume":"9","author":"Aslan","year":"2020","journal-title":"J. Pediatr. Intensive Care"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/jcpt.13010","article-title":"Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review","volume":"44","author":"Bouchard","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e30042","DOI":"10.7759\/cureus.30042","article-title":"Levetiracetam-induced rhabdomyolysis following medication Re-initiation","volume":"14","author":"Boucher","year":"2022","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","volume":"66","author":"Cabral","year":"2020","journal-title":"Rhabdomyolysis. Dis. Mon."},{"key":"B8","doi-asserted-by":"publisher","first-page":"E176-E178","DOI":"10.1002\/mus.25972","article-title":"Levetiracetam-induced rhabdomyolysis: Analysis of reports from the food and drug administration's adverse event reporting system database","volume":"56","author":"Carnovale","year":"2017","journal-title":"Muscle Nerve"},{"key":"B9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.clinbiochem.2017.02.016","article-title":"Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management","volume":"50","author":"Cervellin","year":"2017","journal-title":"Clin. Biochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"Cervellin","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1242\/dev.053348","article-title":"Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons","volume":"137","author":"Chakkalakal","year":"2010","journal-title":"DEVELOPMENT"},{"key":"B12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/WCO.0000000000000803","article-title":"What has been the impact of new drug treatments on epilepsy?","volume":"33","author":"Chen","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"E4-E8","DOI":"10.1111\/hdi.12458","article-title":"A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy","volume":"21","author":"Choi","year":"2017","journal-title":"Hemodial. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00228-006-0131-1","article-title":"Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?","volume":"62","author":"Clark","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3941\/jrcr.v11i4.3092","article-title":"Radiologic findings in gabapentin-induced myositis","volume":"11","author":"Coupal","year":"2017","journal-title":"J. Radiol. Case Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/jat.3808","article-title":"In silico prediction of drug-induced rhabdomyolysis with machine-learning models and structural alerts","volume":"39","author":"Cui","year":"2019","journal-title":"J. Appl. Toxicol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"E1-E2","DOI":"10.1002\/mus.25548","article-title":"Rhabdomyolysis associated with levetiracetam administration","volume":"56","author":"Di Lorenzo","year":"2017","journal-title":"Muscle Nerve"},{"key":"B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40264-016-0473-2","article-title":"Proton pump inhibitors and risk of rhabdomyolysis","volume":"40","author":"Duncan","year":"2017","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5339\/qmj.2020.30","article-title":"Gabapentin-induced myositis in a patient with spinal cord injury - a case report","volume":"2020","author":"Ghosh","year":"2020","journal-title":"Qatar Med. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.5694\/mja13.10769","article-title":"Pregabalin-associated rhabdomyolysis","volume":"199","author":"Gunathilake","year":"2013","journal-title":"Med. J. Aust."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2022.09.026","article-title":"Molecular mechanisms of rhabdomyolysis-induced kidney injury: From bench to bedside","volume":"8","author":"Hebert","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","article-title":"Drug induced rhabdomyolysis","volume":"12","author":"Hohenegger","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s13760-015-0542-9","article-title":"Acute rhabdomyolysis associated with levetiracetam therapy in a child","volume":"116","author":"Incecik","year":"2016","journal-title":"Acta Neurol. Belg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebcr.2014.09.008","article-title":"Creatine phosphokinase elevation exacerbated by levetiracetam therapy","volume":"2","author":"Isaacson","year":"2014","journal-title":"Epilepsy Behav. Case Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1517\/14740338.2016.1139572","article-title":"Rhabdomyolysis induced by antiepileptic drugs: characteristics, treatment and prognosis","volume":"15","author":"Jiang","year":"2016","journal-title":"EXPERT Opin. DRUG Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12991-016-0093-3","article-title":"Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature","volume":"15","author":"Karaoulanis","year":"2016","journal-title":"Ann. Gen. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijscr.2016.07.007","article-title":"Pregabalin- and azithromycin-induced rhabdomyolysis with purpura: An unrecognized interaction: a case report","volume":"26","author":"Kato","year":"2016","journal-title":"Int. J. Surg. Case Rep."},{"key":"B28","first-page":"579","article-title":"Pregabalin and simvastatin: first report of a case of rhabdomyolysis","volume":"37","author":"Kaufman","year":"2012","journal-title":"P T"},{"key":"B29","first-page":"275","article-title":"Levetiracetam-induced rhabdomyolysis: A case report and literature review","volume":"22","author":"Kubota","year":"2017","journal-title":"Neurol. Asia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.seizure.2018.10.005","article-title":"HyperCKemia associated with lacosamide therapy in an elderly patient with focal onset epilepsy","volume":"63","author":"Matsudaira","year":"2018","journal-title":"Seizure"},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.17925\/enr.2018.13.2.113","article-title":"Acute kidney injury and creatine kinase elevation after beginning treatment with levetiracetam","volume":"13","author":"Mena-Martin","year":"2018","journal-title":"Eur. Neurol. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e926064","DOI":"10.12659\/AJCR.926064","article-title":"Suspected levetiracetam-induced rhabdomyolysis: A case report and literature review","volume":"21","author":"Moinuddin","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2013.09.011","article-title":"Statin myotoxicity: a review of genetic susceptibility factors","volume":"24","author":"Needham","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/ccr3.2302","article-title":"A case of gabapentin overdose induced rhabdomyolysis requiring renal replacement therapy","volume":"7","author":"Qiu","year":"2019","journal-title":"Clin. Case Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.lpm.2016.05.014","article-title":"HyperCKemia induced by levetiracetam","volume":"45","author":"Ramon","year":"2016","journal-title":"PRESSE Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2705","DOI":"10.7759\/cureus.2705","article-title":"Rhabdomyolysis: A rare adverse effect of levetiracetam","volume":"10","author":"Rastogi","year":"2018","journal-title":"Cureus"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s10072-018-3421-3","article-title":"Levetiracetam-induced rhabdomyolysis: the first Italian case","volume":"39","author":"Rota","year":"2018","journal-title":"Neurol. Sci."},{"key":"B38","first-page":"409","article-title":"Acute renal failure related to rhabdomyolysis: pathophysiology, diagnosis, and collaborative management","volume":"32","author":"Russell","year":"2005","journal-title":"Nephrol. Nurs. J."},{"key":"B39","first-page":"S63","article-title":"Levetiracetam induced increase in creatine phosphokinase levels","volume":"27","author":"Shahbaz","year":"2017","journal-title":"J. Coll. Physicians Surg. Pak"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7873813","DOI":"10.1155\/2016\/7873813","article-title":"Rhabdomyolysis in a hospitalized 16-year-old boy: A rarely reported underlying cause","volume":"2016","author":"Singh","year":"2016","journal-title":"Case Rep. Pediatr."},{"key":"B41","first-page":"105","article-title":"Myotoxicity induced by antiepileptic drugs: Could be a rare but serious adverse event?","volume":"51","author":"Siniscalchi","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.06.002","article-title":"Levetiracetam as a possible contributor to acute kidney injury","volume":"36","author":"Spengler","year":"2014","journal-title":"Clin. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e230851","DOI":"10.1136\/bcr-2019-230851","article-title":"Rhabdomyolysis: a rare adverse effect of levetiracetam","volume":"12","author":"Thomas","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1254\/fpj.152.275","article-title":"Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy","volume":"152","author":"Tokudome","year":"2018","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"B45","first-page":"58","article-title":"Rhabdomyolysis: pathogenesis, diagnosis, and treatment","volume":"15","author":"Torres","year":"2015","journal-title":"Ochsner J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: Emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1051866","DOI":"10.3389\/fmolb.2022.1051866","article-title":"Ferroptosis and its role in skeletal muscle diseases","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.semvascsurg.2015.01.007","article-title":"Biochemical markers of acute limb ischemia, rhabdomyolysis, and impact on limb salvage","volume":"27","author":"Watson","year":"2014","journal-title":"Semin. Vasc. Surg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ki.1996.48","article-title":"Rhabdomyolysis and myohemoglobinuric acute renal failure","volume":"49","author":"Zager","year":"1996","journal-title":"KIDNEY Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"806081","DOI":"10.3389\/fcell.2022.806081","article-title":"Atorvastatin induces mitochondria-dependent ferroptosis via the modulation of nrf2-xCT\/GPx4 Axis","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1080\/21655979.2022.2036916","article-title":"Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population","volume":"13","author":"Zhao","year":"2022","journal-title":"BIOENGINEERED"},{"key":"B52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1021\/acs.chemrestox.0c00347","article-title":"Quantitative structure-activity relationship (QSAR) model for the severity prediction of drug-induced rhabdomyolysis by using random forest","volume":"34","author":"Zhou","year":"2021","journal-title":"Chem. Res. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1197470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:15:38Z","timestamp":1696259738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1197470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":52,"alternative-id":["10.3389\/fphar.2023.1197470"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1197470","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"article-number":"1197470"}}